Strategic Realignment of Eversense CGM Commercial Operations to Advance Sustainable Development Goals

Introduction: Fostering Good Health and Well-being (SDG 3)

On September 3, 2025, PHC Holdings Corporation and its subsidiary, Ascensia Diabetes Care, announced a memorandum of understanding with Senseonics Holdings, Inc. This agreement outlines the transfer of commercial operations for the Eversense® Continuous Glucose Monitoring (CGM) systems to Senseonics. This strategic initiative is designed to enhance the accessibility and growth of innovative diabetes care technology, directly contributing to SDG 3 by improving the management of non-communicable diseases and promoting well-being for individuals living with diabetes. The transfer is targeted for completion by January 1, 2026, pending a definitive agreement.

Rationale for Restructuring: Enhancing Innovation and Infrastructure (SDG 9)

The decision to unify Eversense operations within Senseonics is driven by a strategy to build a more resilient and efficient infrastructure for this key medical innovation. This move aligns with SDG 9 by fostering innovation and upgrading industrial capabilities within the healthcare technology sector. The primary objectives are:

• To integrate research and development, manufacturing, and commercial activities, thereby accelerating the growth and market potential of the Eversense CGM system.
• To address the divergence between the specialized go-to-market approach for Eversense and Ascensia’s core blood glucose monitoring business.
• To align with PHC Group’s long-term “Value Creation Plan,” which prioritizes operational efficiency and strategic portfolio management to support sustainable industrialization.

Implementation Plan: Ensuring Decent Work and Economic Growth (SDG 8)

The transition is structured to ensure continuity and support sustainable economic growth while protecting employment, in line with the principles of SDG 8. The process will involve several key steps:

1. The majority of Ascensia’s Eversense commercial team, including key leadership, is expected to transition to Senseonics, preserving specialized jobs and expertise.
2. Transition Service Agreements will be utilized to facilitate a smooth handover of global commercial operations as Senseonics establishes its own infrastructure.
3. The companies are committed to ensuring minimal disruption for all stakeholders, including patients, healthcare providers, and business partners, thereby maintaining stable market conditions.

Partnership Evolution for Global Goals (SDG 17)

This operational transfer represents an evolution of the partnership between PHC Group, Ascensia, and Senseonics, demonstrating a commitment to SDG 17. While the operational structure is changing, the collaboration’s core goal remains: to advance global health outcomes. Key aspects of this evolved partnership include:

• A shared belief that unifying operations within Senseonics is the most effective path to realize the full potential of the Eversense 365 system, the world’s first one-year CGM.
• PHC Group’s continued investment in Senseonics, signaling a long-term commitment to the partnership and the broader goal of improving diabetes care.
• A collaborative transition process designed to ensure the continued success and momentum of the Eversense brand, reinforcing the strength of partnerships in achieving sustainable development objectives.

1. Which SDGs are addressed or connected to the issues highlighted in the article?

• SDG 3: Good Health and Well-being

  The article is centered on a medical device, the Eversense® Continuous Glucose Monitoring (CGM) system, designed for diabetes management. This directly relates to ensuring healthy lives and promoting well-being, as the product helps people manage a chronic non-communicable disease (NCD). The mission of the companies involved, such as PHC Holdings Corporation’s goal of “contributing to the health of society through healthcare solutions,” reinforces this connection.

• SDG 9: Industry, Innovation, and Infrastructure

  The article discusses the development and commercialization of an innovative medical technology, the “Eversense 365, the world’s first and only one-year CGM system.” The strategic business decision to unite “Eversense R&D, manufacturing, and commercial activities” is aimed at building a resilient infrastructure within Senseonics to “accelerate growth and realize its full potential,” which aligns with the goal of fostering innovation and upgrading industrial capabilities.

• SDG 17: Partnerships for the Goals

  The entire article describes a multi-stakeholder partnership between private sector companies: PHC Holdings Corporation, its subsidiary Ascensia Diabetes Care, and Senseonics Holdings, Inc. It details their collaboration, which began with a distribution agreement in 2020 and is now evolving through a memorandum of understanding to transfer commercial operations. This partnership mobilizes expertise and resources to advance a shared healthcare goal.

2. What specific targets under those SDGs can be identified based on the article’s content?

• Target 3.4: Reduce premature mortality from non-communicable diseases

  By providing an advanced tool for managing diabetes, a major NCD, the Eversense CGM system directly contributes to the treatment aspect of this target. The article states that the companies’ mission is to “empower those living with diabetes through innovative solutions that simplify and improve their lives,” which is essential for preventing the long-term complications and premature mortality associated with poorly managed diabetes.

• Target 9.5: Enhance scientific research and upgrade technological capabilities

  The article highlights a specific technological innovation: “Eversense 365, the world’s first and only one-year CGM system.” The business agreement to bring “R&D, manufacturing, and commercialization together” is a strategic move to enhance the technological and commercial capabilities of Senseonics, fostering further innovation and growth in the medical device sector.

• Target 17.17: Encourage and promote effective public-private and civil society partnerships

  The collaboration between PHC Group, Ascensia, and Senseonics is a clear example of a private-private partnership. The article details the evolution of this partnership, from an initial distribution agreement to a planned transfer of operations, demonstrating a dynamic collaboration built on shared goals and resources to bring a healthcare solution to a global market.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

• Indicator for Target 3.4: Availability of advanced medical technologies for NCDs

  The article implies this indicator through its focus on the commercialization and distribution of the Eversense CGM system. The “successful U.S. Eversense 365 launch” and the strategic goal to “accelerate growth” serve as proxies for measuring the increased availability and adoption of this technology for diabetes management.

• Indicator for Target 9.5: Development and launch of innovative products

  The existence of the “Eversense 365” system, described as the “world’s first and only one-year CGM system,” is a direct indicator of successful research and innovation. The corporate restructuring to “unite Eversense R&D, manufacturing, and commercial activities” is a strategic action aimed at improving the efficiency of the innovation-to-market pipeline.

• Indicator for Target 17.17: Number and value of multi-stakeholder partnerships

  The article itself is evidence of such a partnership. The “memorandum of understanding” between Ascensia and Senseonics, building on their 2020 collaboration, serves as a qualitative indicator. Furthermore, the global reach of the partnership is implied by Ascensia’s distribution of products in “more than 100 countries,” suggesting the scale and impact of their collaborative efforts.

4. Table of SDGs, Targets, and Indicators

Source: finance.yahoo.com